AIA Group Ltd Has $15.19 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

AIA Group Ltd boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,313 shares of the biopharmaceutical company’s stock after buying an additional 3,081 shares during the quarter. AIA Group Ltd’s holdings in Alnylam Pharmaceuticals were worth $15,191,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Mirabella Financial Services LLP lifted its holdings in shares of Alnylam Pharmaceuticals by 83.4% during the third quarter. Mirabella Financial Services LLP now owns 5,447 shares of the biopharmaceutical company’s stock worth $2,479,000 after purchasing an additional 2,477 shares during the period. CTC Alternative Strategies Ltd. bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $682,000. Allworth Financial LP lifted its holdings in Alnylam Pharmaceuticals by 86.7% during the 3rd quarter. Allworth Financial LP now owns 1,290 shares of the biopharmaceutical company’s stock worth $588,000 after buying an additional 599 shares during the period. IFP Advisors Inc grew its position in shares of Alnylam Pharmaceuticals by 145.5% in the 3rd quarter. IFP Advisors Inc now owns 491 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 291 shares during the last quarter. Finally, Groupama Asset Managment increased its stake in shares of Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after buying an additional 2,483,697 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $314.80 on Thursday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The company’s 50-day moving average is $338.90 and its 200-day moving average is $406.96. The stock has a market capitalization of $41.75 billion, a PE ratio of 184.09 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The firm had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s quarterly revenue was up 84.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.65) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALNY. Oppenheimer began coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective for the company. Leerink Partners decreased their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. HC Wainwright restated a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 18th. Finally, Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $468.84.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the sale, the executive vice president directly owned 21,264 shares of the company’s stock, valued at $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 9,577 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the completion of the sale, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. This represents a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,923 shares of company stock valued at $18,072,087 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.